Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.
Type:
Grant
Filed:
June 23, 2014
Date of Patent:
December 8, 2015
Assignee:
Protea Biosciences, Inc.
Inventors:
Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li
Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
October 26, 2012
Publication date:
October 30, 2014
Inventors:
Bronislava Gedulin, Michael Grey, Niall O'Donnell
Abstract: Provided herein are pediatric dosage forms for use in the treatment of a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of the pediatric dosage form comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are said pediatric dosage form for use in the treatment of a pediatric liver disease, for use in decreasing the levels of serum bile acids or hepatic bile acids, for use in the treatment of pruritis, for use in reducing liver enzymes or bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
October 26, 2012
Publication date:
August 28, 2014
Applicant:
Lumena Pharmaceuticals, Inc.
Inventors:
Bronislava Gedulin, Michael Grey, Niall O'Donnell
Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.
Type:
Grant
Filed:
June 1, 2012
Date of Patent:
July 29, 2014
Assignee:
Protea Biosciences, Inc.
Inventors:
Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li
Abstract: A compound may generally comprise the formula: wherein R1 is independently selected from C2-C10 alkyl or substituted alkyl, R2 is independently selected from the group consisting of —H and C1-C6 alkyl or substituted alkyl, X is selected from the group consisting of —NH— and —O—, Y is a carbohydrate, and m is an integer from 1 to 8. The compound may comprise a non-ionic acid labile surfactant. The compound may be used to facilitate solubilization of proteins and other molecules in an aqueous environment.
Type:
Application
Filed:
June 1, 2012
Publication date:
December 6, 2012
Inventors:
Matthew Jacob Powell, Trust T. Razunguzwa, Miaosheng Li
Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.
Type:
Application
Filed:
May 14, 2009
Publication date:
March 11, 2010
Applicant:
SANOFI-AVENTIS DEUTUSCHLAND GMBH
Inventors:
Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer
Abstract: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.
Type:
Application
Filed:
May 14, 2009
Publication date:
February 11, 2010
Applicant:
SANOFI-AVENTIS DEUTUSCHLAND GMBH
Inventors:
Heiner Glombik, Wendelin Frick, Stefan Theis, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer